CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality
Site Search
Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.
Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis. About 17% of individuals with CF who had Pseudomonas infections last year had multi-drug resistant strains.
Although adults with cystic fibrosis are at a significantly higher risk of developing colorectal cancer than the general population, colonoscopy screening is an effective way to prevent and treat colorectal cancer by helping to detect and remove polyps. People with CF should be screened starting at age 40 (or 30 for those who have had a transplant). Find out how early screening can help reduce the risk.
You can best manage your health when you know what to expect, what resources you can use, and a community of people with whom you can share your experiences.
The Cystic Fibrosis Foundation, alongside the CF community, urges Congress to pass the PASTEUR Act and the HELP Copays Act.
Scientists around the world agree that global innovation is needed to address the shortage of effective antibiotics. Our Infection Research Initiative supports much-needed research and development, but new policies are needed to promote a sustainable, robust antibiotics pipeline and a marketplace that rewards innovation.